子宫内膜异位症的药物治疗

doi:10.6040/j.issn.1671-7554.0.2019.519

摘要/Abstract

摘要： 子宫内膜异位症(EMs)是一种慢性、复发性疾病,保守性手术难以治愈,因此,药物治疗具有重要地位,治疗EMs疼痛常用而有效的药物有非甾体类抗炎药(NSAIDs)、口服避孕药、孕激素类药物、内美通或孕三烯酮、促性腺激素释放激素激动剂(GnRH-a)或拮抗剂及中医中药等。术后长期药物维持治疗控制疼痛和预防复发,近年来得到推崇并已经达成中国专家共识。

关键词: 子宫内膜异位症, 药物治疗, 维持治疗, 促性腺激素释放激素激动剂, 促性腺激素释放激素拮抗剂, 孕激素

Abstract: Endometriosis(EMs)is a chronic and recurrent disease, and can hardly be cured by conservative surgery, so the medical treatment is very important. Many drugs have been developed for relieving pain symptoms associated with EMs, such as nonsteroids anti-inflammatory drugs(NSAIDs), conjugated oral contraceptives, progestins, gestrinone, 山东大学学报 (医学版)57卷6期 -彭超,等.子宫内膜异位症的药物治疗 \=-gonadotropin-releasing hormone-agonists or GnRH-antagonists, and traditional Chinese medicine. Experts consensus has been achieved and published in 2018 in China on long-term maintenance therapy postoperatively to relieve pain and to prevent recurrence of EMs.

Key words: Endometriosis, Medical treatment, Maintenance therapy, Gonadotropin-releasing hormone-agonists, Gonadotropin-releasing hormone-antagonists, Progestins

中图分类号:

R711.71

彭超,周应芳. 子宫内膜异位症的药物治疗[J]. 山东大学学报 (医学版), 2019, 57(6): 46-50.

PENG Chao, ZHOU Yingfang. Medical treatment of endometriosis: an update[J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 46-50.

参考文献

[1] 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南[J]. 中华妇产科杂志, 2015, 50(3): 161-169.
[2] 周应芳. 子宫内膜异位症患者长期管理的必要性[J]. 中华妇产科杂志, 2017, 52(3): 145-146.
[3] 中华医师协会妇产科医师分会子宫内膜异位症专业委员会,中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症长期管理中国专家共识[J]. 中华妇产科杂志, 2018, 53(12): 836-841.
[4] Falcone T, Flyckt R. Clinical management of endometriosis[J]. Obstet Gynecol, 2018, 131(3): 557-571.
[5] Singh SS, Suen MW. Surgery for endometriosis: beyond medical therapies[J]. Fertil Steril, 2017, 107(3): 549-554.
[6] Chaichian S, Kabir A, Mehdizadehkashi A, et al. Comparing the efficacy of surgery and medical therapy for pain management in endometriosis: a systematic review and meta-analysis[J]. Pain Physician, 2017, 20(3): 185-195.
[7] Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis[J]. Hum Reprod, 2014, 29(3): 400-412.
[8] Vercellini P, Buggio L, Somigliana E. Role of medical therapy in the management of deep rectovaginal endometriosis[J]. Fertil Steril, 2017, 108(6): 913-930.
[9] Mama ST. Advances in the management of endometriosis in the adolescent[J]. Curr Opin Obstet Gynecol, 2018, 30(5): 326-330.
[10] Kho RM, Andres MP, Borrelli GM, et al. Surgical treatment of different types of endometriosis: comparison of major society guidelines and preferred clinical algorithms[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 51: 102-110. doi:10.1016/j.bpobgyn.2018.01.020.
[11] Vercellini P, Buggio L, Frattaruolo MP, et al. Medical treatment of endometriosis-related pain[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 51: 68-91. doi:10.1016/j.bpobgyn.2018.01.015.
[12] ACOG Committee Opinion No. 760 summary: dysmenorrhea and endometriosis in the adolescent[J]. Obstet Gynecol, 2018, 132(6):1517-1518.
[13] Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis[J]. Cochrane Database Syst Rev, 2017, 1: CD004753. doi:10.1002/14651858.CD004753.pub4.
[14] 程利南, 狄文, 丁岩, 等. 女性避孕方法临床应用的中国专家共识[J]. 中华妇产科杂志, 2018, 53(7): 433-447.
[15] 复方口服避孕药临床应用中国专家共识专家组. 复方口服避孕药临床应用中国专家共识[J]. 中华妇产科杂志, 2015, 50(2): 81-91.
[16] Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive[J]. J Endocrinol Invest, 2016, 39(8): 923-931.
[17] Buggio L, Somigliana E, Barbara G, et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine[J]. Expert Opin Pharmacother, 2017, 18(15): 1569-1581.
[18] Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy[J]. Fertil Steril, 2017, 107(3): 537-548.
[19] Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108(4): 673-678.
[20] Andres Mde P, Lopes LA, Baracat EC, et al. Dienogest in the treatment of endometriosis: systematic review[J]. Arch Gynecol Obstet, 2015, 292(3): 523-529.
[21] Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate(104 mg/0.65 mL): a systematic review[J]. Contraception, 2016, 94(3): 202-215.
[22] Carvalho N, Margatho D, Cursino K, et al. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial[J]. Fertil Steril, 2018, 110(6): 1129-1136.
[23] Kim ML, Cho YJ, Kim MK, et al. The efficacy of long-term maintenance therapy with a levonorgestrel-releasing intrauterine system for prevention of ovarian endometrioma recurrence[J]. Int J Gynaecol Obstet, 2016, 134(3): 256-259.
[24] 郎景和, 冷金花, 王泽华, 等. 促性腺激素释放激素激动剂在子宫内膜异位症和子宫平滑肌瘤治疗中的应用专家意见[J]. 中华妇产科杂志, 2017, 52(2): 77-81.
[25] 郎景和,崔恒,戴毅,等. 2015年子宫内膜异位症的诊治指南专家解读[J]. 中华妇产科杂志, 2017, 52(12): 857-861.
[26] 贾双征, 冷金花, 孙蓬然, 等. 黑升麻提取物对子宫内膜异位症患者GnRH-a治疗期间低雌激素症状及生命质量的影响[J]. 中华妇产科杂志, 2015, 50(9): 692-693.
[27] Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist[J]. N Engl J Med, 2017, 377(1): 28-40.
[28] Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies[J]. Obstet Gynecol, 2018, 132(1): 147-160.
[29] Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments[J]. Expert Opin Biol Ther, 2019, 19(4): 343-360.
[30] Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis[J]. Expert Opin Pharmacother, 2017, 18(13): 1391-1397.
[31] Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold[J]. Hum Reprod, 2019, 34(2): 193-199.
[32] Markham A. Relugolix: first global approval[J]. Drugs, 2019, 79(6): 675-679.
[33] 段华, 汪沙, 郝敏, 等. 孕三烯酮使用中不规则子宫出血干预的多中心、随机、平行对照研究[J]. 中华妇产科杂志, 2016, 51(2): 98-102. DUAN Hua, WANG Sha, HAO Min, et al. Research of gestrinone-related abnormal uterine bleeding and the intervention in the treatment: a multi-center, randomized, controlled clinical trial[J]. Chinese Journal of Obstetrics and Gynecology, 2016, 51(2): 98-102.
[34] 周应芳. 子宫腺肌病药物治疗原则及注意事项[J]. 中国实用妇科与产科杂志, 2017, 33(2): 157-160. ZHOU Yingfang. Principles and precautions of medical treatment for adenomyosis of the uterus[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2017, 33(2): 157-160.
[35] Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments[J]. Expert Opin Investig Drugs, 2018, 27(5): 445-458.

相关文章 15

[1]	颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34.
[2]	彭超,周应芳. 子宫腺肌病的药物治疗进展[J]. 山东大学学报 (医学版), 2022, 60(7): 20-25.
[3]	冷金花,史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5.
[4]	陈忠绍,褚然,李明宝,张向宁. MRKH综合征相关腹股沟子宫疝修补术后腹壁瘢痕子宫内膜异位症1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(5): 114-117.
[5]	林雪艳,张灿灿,田民乐,田永杰. 聚腺苷酸二磷酸核糖聚合酶-1在子宫内膜异位症中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(2): 27-31.
[6]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[7]	单婧,王晓秋,李大金. NK细胞参与子宫内膜异位症及其不孕的分子机制[J]. 山东大学学报 (医学版), 2021, 59(8): 8-13.
[8]	丁菲,姜洁. 姜黄素对子宫内膜癌孕激素抵抗的影响[J]. 山东大学学报 (医学版), 2021, 59(4): 35-41.
[9]	梁炎春,叶海花,陆丽美,戴郁菁,程谦益,蔡婉玲,曾涵秋,陈杏欢,王兴,韦雅婧,杨如玉. 慢性子宫内膜炎对子宫内膜异位症相关性不孕妊娠结局的影响[J]. 山东大学学报 (医学版), 2021, 59(3): 55-59.
[10]	薛源,林雪艳,徐歌,田永杰. 低氧诱导因子-1α在子宫内膜异位症患者血清中的表达和对在位子宫内膜间质细胞上皮-间质转化的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 41-47.
[11]	潘虹江,王焕昇,裴发军,杨明山. 孤立性膀胱子宫内膜异位症1例[J]. 山东大学学报 (医学版), 2021, 59(2): 122-124.
[12]	王国云,王凯,袁明,陈子江. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报 (医学版), 2021, 59(10): 1-16.
[13]	冷金花,史精华. 子宫内膜异位症长期管理策略[J]. 山东大学学报 (医学版), 2019, 57(6): 1-5.
[14]	姚书忠,梁炎春,韦雅婧. 子宫内膜异位症的手术治疗[J]. 山东大学学报 (医学版), 2019, 57(6): 6-15.
[15]	张信美,钱洪浪. 子宫内膜异位症的临床表现[J]. 山东大学学报 (医学版), 2019, 57(6): 16-22.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed